Of the seven NSCLC patients harboring EGFR mutation enrolled in this study, who developed disease progression and had acquired EGFR-TKI resistance, the plasma was sampled for quantifying miR-214 expression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.